Literature DB >> 14621343

Short-term buprenorphine maintenance: treatment outcome.

Marc Galanter1, Helen Dermatis, Richard Resnick, Robert Maslansky, Erna Neumann.   

Abstract

Fifty-two heroin addicts were inducted onto buprenorphine under the care of psychiatric residents in a setting modeled on office practice. Subjects were maintained on a protocol of six weeks of 16 mg daily dosing, then tapered to zero dose up to week 16, and maintained on placebo through week 18. Of 44 subjects who continued after the first induction dose, 11 terminated during maintenance, 17 during taper; and 16 while on zero dose. Twice weekly urine toxicologies showed significant successive declines in samples positive for heroin use across these three periods: 70%, 41%, and 20%, respectively. Among historical variables, only prior AA attendance distinguished subjects who achieved zero dose from those who did not. A comparison with recent studies suggests that relatively inexperienced office-based physicians can maintain patients on buprenorphine at a level comparable to that reported for research clinic settings, but with comparable rates of heroin abstinence. These findings are discussed in light of potential options for office-based opioid maintenance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14621343     DOI: 10.1300/J069v22n03_04

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  4 in total

Review 1.  Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches?

Authors:  Erik W Gunderson; David A Fiellin
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 2.  The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.

Authors:  Kelly E Dunn; Stacey C Sigmon; Eric C Strain; Sarah H Heil; Stephen T Higgins
Journal:  Drug Alcohol Depend       Date:  2011-07-08       Impact factor: 4.492

3.  Buprenorphine tapering schedule and illicit opioid use.

Authors:  Walter Ling; Maureen Hillhouse; Catherine Domier; Geetha Doraimani; Jeremy Hunter; Christie Thomas; Jessica Jenkins; Albert Hasson; Jeffrey Annon; Andrew Saxon; Jeffrey Selzer; Joshua Boverman; Richard Bilangi
Journal:  Addiction       Date:  2009-02       Impact factor: 6.526

4.  Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study.

Authors:  Amit Chakrabarti; George E Woody; Margaret L Griffin; Geetha Subramaniam; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2009-11-30       Impact factor: 4.492

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.